Polymeric cyclosporine-A nanoparticles for ocular application

Area of Science:

• Ophthalmic drug delivery
• Nanotechnology
• Pharmacokinetics

Background:

• Cyclosporine A (CsA) is crucial for treating ocular inflammatory conditions.
• Conventional CsA formulations face challenges in achieving sustained ocular drug levels.
• Nanoparticle-based drug delivery offers potential for enhanced ocular penetration and retention.

Purpose of the Study:

• To develop and characterize cationic Eudragit RS 100 nanoparticles (EPNs) for ocular delivery of CsA.
• To evaluate the in vitro drug release profile of CsA from EPNs.
• To assess the in vivo ocular distribution and residence time of CsA delivered via EPNs in a preclinical model.

Main Methods:

• Cyclosporine A (CsA) was encapsulated into cationic Eudragit RS 100 nanoparticles (EPNs).
• Physicochemical properties of EPNs were assessed over a 6-month storage period.
• In vitro drug release studies were conducted.
• In vivo ocular distribution was evaluated in sheep eyes using enzyme immune assay (EIA) after topical application.

Main Results:

• EPNs demonstrated successful incorporation and stability of CsA over 6 months.
• In vitro studies showed sustained release of CsA from the nanoparticles.
• In vivo studies revealed prolonged residence time of CsA in the vitreous humour following topical EPN administration.

Conclusions:

• Cationic Eudragit RS 100 nanoparticles provide a promising platform for sustained ocular delivery of cyclosporine A.
• The positively charged nanoparticles enhance drug retention in deeper ocular tissues, potentially improving therapeutic efficacy.
• This formulation strategy warrants further investigation for managing ocular diseases requiring long-term CsA treatment.